IQVIA (NYSE:IQV) Stock Price Expected to Rise, Morgan Stanley Analyst Says

IQVIA (NYSE:IQV) had its price objective upped by equities researchers at Morgan Stanley from $245.00 to $250.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical research company’s stock. Morgan Stanley’s target price indicates a potential upside of 24.07% from the stock’s current price.

Other equities analysts have also recently issued research reports about the company. Barclays reduced their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. JPMorgan Chase & Co. lowered their price objective on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Redburn Atlantic began coverage on shares of IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 price target for the company. William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Finally, UBS Group decreased their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research note on Friday. Five research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average price target of $251.67.

IQVIA Stock Down 2.6 %

Shares of IQV traded down $5.47 during midday trading on Tuesday, reaching $201.51. 615,098 shares of the stock were exchanged, compared to its average volume of 1,396,460. The company has a current ratio of 0.84, a quick ratio of 0.81 and a debt-to-equity ratio of 2.12. IQVIA has a 52 week low of $187.62 and a 52 week high of $261.73. The company’s 50 day moving average is $200.77 and its two-hundred day moving average is $219.09. The company has a market capitalization of $36.57 billion, a P/E ratio of 26.85, a PEG ratio of 2.25 and a beta of 1.48.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, sell-side analysts anticipate that IQVIA will post 10.81 earnings per share for the current year.

Insider Activity at IQVIA

In other news, Director John G. Danhakl acquired 1,275 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The shares were bought at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the acquisition, the director now directly owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On IQVIA

A number of hedge funds have recently bought and sold shares of IQV. Lee Danner & Bass Inc. bought a new stake in shares of IQVIA in the 4th quarter worth about $44,000. Whittier Trust Co. of Nevada Inc. raised its stake in IQVIA by 4.9% during the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 51,614 shares of the medical research company’s stock valued at $10,142,000 after buying an additional 2,432 shares in the last quarter. Douglass Winthrop Advisors LLC lifted its holdings in IQVIA by 7.6% during the 4th quarter. Douglass Winthrop Advisors LLC now owns 471,533 shares of the medical research company’s stock worth $92,661,000 after buying an additional 33,455 shares during the last quarter. Holderness Investments Co. lifted its stake in IQVIA by 22.9% during the fourth quarter. Holderness Investments Co. now owns 2,391 shares of the medical research company’s stock worth $470,000 after purchasing an additional 445 shares during the last quarter. Finally, Northwest & Ethical Investments L.P. boosted its holdings in shares of IQVIA by 6.9% in the 4th quarter. Northwest & Ethical Investments L.P. now owns 14,319 shares of the medical research company’s stock valued at $2,814,000 after buying an additional 919 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.